Search
SCY-635
go.drugbank.com/drugs/DB12451InvestigationalSCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.
Rolofylline
go.drugbank.com/drugs/DB12670InvestigationalRolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.
Phenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalEuropean countries under the trade name “Coaxil” as well as in Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or
ATL-104
go.drugbank.com/drugs/DB05670InvestigationalATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
OT-551
go.drugbank.com/drugs/DB05650InvestigationalIt is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular … degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD.
Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB21765ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde.
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde.
Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB17996ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde.